Artificial Intelligence Is Future Of Postmarketing Surveillance, US FDA’s Marks Says

 
• By Sue Sutter

CBER director’s vision for a national safety surveillance system includes use of AI and natural language processing to enable near-real time signal detection from adverse event reports.

FDA circuit board
FDA has had to bridge gaps in access to postmarketing surveillance data for COVID-19 vaccines. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

More from AI

More from Advanced Technologies